相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Extracellular Signal-Regulated Kinases 1 and 2 Regulate the Balance Between Eccentric and Concentric Cardiac Growth
Izhak Kehat et al.
CIRCULATION RESEARCH (2011)
MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutation
Xue Wu et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation
Talita M. Marin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy
Izhak Kehat et al.
ANALYSIS OF CARDIAC DEVELOPMENT: FROM EMBRYO TO OLD AGE (2010)
Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms
Marco Tartaglia et al.
YEAR IN HUMAN AND MEDICAL GENETICS: NEW TRENDS IN MENDELIAN GENETICS (2010)
Molecular Pathways Underlying Cardiac Remodeling During Pathophysiological Stimulation
Izhak Kehat et al.
CIRCULATION (2010)
Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
Christine A. Pratilas et al.
CLINICAL CANCER RESEARCH (2010)
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Xonia Carvajal-Vergara et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects
MI Kontaridis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease
M Tartaglia et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1
WD Li et al.
CURRENT BIOLOGY (2005)
Germline mutations in HRAS proto-oncogene cause Costello syndrome
Y Aoki et al.
NATURE GENETICS (2005)
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
PM LoRusso et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer
S Rao et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
M Tartaglia et al.
NATURE GENETICS (2003)
Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene
MC Digilio et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
M Tartaglia et al.
NATURE GENETICS (2001)
The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice
OF Bueno et al.
EMBO JOURNAL (2000)
分享论文
